By TOM MURPHY, Associated Press Health Writer

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Related Articles

Californians’ economic hopes drop 23% since Trump election

China says it will work with US to resolve issues related to TikTok

US stocks slip as Wall Street sees both good and bad in Big Tech profits, US-China relations

China agrees to purchase 25 million metric tons of U.S. soybeans annually, treasury secretary says

Halloween is a challenge for chocolatiers as high prices bite

Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. That made up over half of the

See Full Page